[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fWzQWQefwz6yS8IoMi8L3IaZGnSp3GyJYU65v-G4UFLM":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":35,"rows":42},"Johannes Gutenberg University Mainz",[4],155,false,16,4,42810,0,127,[14,17,20,23,25,27,29,32],{"name":15,"count":16},"Airway Morbidity",7,{"name":18,"count":19},"Coronary Artery Disease",5,{"name":21,"count":22},"Pediatric Oncology",3,{"name":24,"count":22},"Hepatocellular Carcinoma",{"name":26,"count":22},"Airway Management",{"name":28,"count":22},"Cancer",{"name":30,"count":31},"Fatty Liver, Nonalcoholic",2,{"name":33,"count":31},"Heart Failure",[],[36,37,38,39,40,41],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[43,73,91,109,127,155,173,191,217,243,271,289,307,333,360,385,409,443,480,504,531,549,575,602,627,651,676,694,712,736,761,786,810,833,871],{"intervention":44,"totalTrials":45,"cells":46},"Telmisartan",1,{"EARLY_PHASE1":47,"PHASE1":49,"PHASE2":51,"PHASE3":53,"PHASE4":55,"NA":71},{"trials":48,"activeCount":11},[],{"trials":50,"activeCount":11},[],{"trials":52,"activeCount":11},[],{"trials":54,"activeCount":11},[],{"trials":56,"activeCount":11},[57],{"nctId":58,"briefTitle":59,"status":60,"phases":61,"primaryCompletion":62,"completion":62,"start":63,"enrollment":64,"conditions":65,"interventions":67},"NCT01180205","Telmisartan, Amlodipine and Flow Mediated Dilation","UNKNOWN",[40],"2011-10","2010-08",576,[66],"Hypertension",[44,68,69,70],"Amlodipine","Olmesartan medoxomil","Hydrochlorothiazide",{"trials":72,"activeCount":11},[],{"intervention":68,"totalTrials":45,"cells":74},{"EARLY_PHASE1":75,"PHASE1":77,"PHASE2":79,"PHASE3":81,"PHASE4":83,"NA":89},{"trials":76,"activeCount":11},[],{"trials":78,"activeCount":11},[],{"trials":80,"activeCount":11},[],{"trials":82,"activeCount":11},[],{"trials":84,"activeCount":11},[85],{"nctId":58,"briefTitle":59,"status":60,"phases":86,"primaryCompletion":62,"completion":62,"start":63,"enrollment":64,"conditions":87,"interventions":88},[40],[66],[44,68,69,70],{"trials":90,"activeCount":11},[],{"intervention":69,"totalTrials":45,"cells":92},{"EARLY_PHASE1":93,"PHASE1":95,"PHASE2":97,"PHASE3":99,"PHASE4":101,"NA":107},{"trials":94,"activeCount":11},[],{"trials":96,"activeCount":11},[],{"trials":98,"activeCount":11},[],{"trials":100,"activeCount":11},[],{"trials":102,"activeCount":11},[103],{"nctId":58,"briefTitle":59,"status":60,"phases":104,"primaryCompletion":62,"completion":62,"start":63,"enrollment":64,"conditions":105,"interventions":106},[40],[66],[44,68,69,70],{"trials":108,"activeCount":11},[],{"intervention":70,"totalTrials":45,"cells":110},{"EARLY_PHASE1":111,"PHASE1":113,"PHASE2":115,"PHASE3":117,"PHASE4":119,"NA":125},{"trials":112,"activeCount":11},[],{"trials":114,"activeCount":11},[],{"trials":116,"activeCount":11},[],{"trials":118,"activeCount":11},[],{"trials":120,"activeCount":11},[121],{"nctId":58,"briefTitle":59,"status":60,"phases":122,"primaryCompletion":62,"completion":62,"start":63,"enrollment":64,"conditions":123,"interventions":124},[40],[66],[44,68,69,70],{"trials":126,"activeCount":11},[],{"intervention":128,"totalTrials":45,"cells":129},"Ticagrelor",{"EARLY_PHASE1":130,"PHASE1":132,"PHASE2":134,"PHASE3":136,"PHASE4":138,"NA":153},{"trials":131,"activeCount":11},[],{"trials":133,"activeCount":11},[],{"trials":135,"activeCount":11},[],{"trials":137,"activeCount":11},[],{"trials":139,"activeCount":11},[140],{"nctId":141,"briefTitle":142,"status":143,"phases":144,"primaryCompletion":145,"completion":146,"start":147,"enrollment":148,"conditions":149,"interventions":150},"NCT01700322","Endothelium, Stenting, and Antiplatelet Therapy (EST) - Clopidogrel, Prasugrel, Ticagrelor Study","COMPLETED",[40],"2016-07","2016-09","2012-08",126,[18],[128,151,152],"Clopidogrel","Prasugrel",{"trials":154,"activeCount":11},[],{"intervention":151,"totalTrials":45,"cells":156},{"EARLY_PHASE1":157,"PHASE1":159,"PHASE2":161,"PHASE3":163,"PHASE4":165,"NA":171},{"trials":158,"activeCount":11},[],{"trials":160,"activeCount":11},[],{"trials":162,"activeCount":11},[],{"trials":164,"activeCount":11},[],{"trials":166,"activeCount":11},[167],{"nctId":141,"briefTitle":142,"status":143,"phases":168,"primaryCompletion":145,"completion":146,"start":147,"enrollment":148,"conditions":169,"interventions":170},[40],[18],[128,151,152],{"trials":172,"activeCount":11},[],{"intervention":152,"totalTrials":45,"cells":174},{"EARLY_PHASE1":175,"PHASE1":177,"PHASE2":179,"PHASE3":181,"PHASE4":183,"NA":189},{"trials":176,"activeCount":11},[],{"trials":178,"activeCount":11},[],{"trials":180,"activeCount":11},[],{"trials":182,"activeCount":11},[],{"trials":184,"activeCount":11},[185],{"nctId":141,"briefTitle":142,"status":143,"phases":186,"primaryCompletion":145,"completion":146,"start":147,"enrollment":148,"conditions":187,"interventions":188},[40],[18],[128,151,152],{"trials":190,"activeCount":11},[],{"intervention":192,"totalTrials":45,"cells":193},"Desmotabs",{"EARLY_PHASE1":194,"PHASE1":196,"PHASE2":198,"PHASE3":200,"PHASE4":202,"NA":215},{"trials":195,"activeCount":11},[],{"trials":197,"activeCount":11},[],{"trials":199,"activeCount":11},[],{"trials":201,"activeCount":11},[],{"trials":203,"activeCount":11},[204],{"nctId":205,"briefTitle":206,"status":207,"phases":208,"primaryCompletion":209,"completion":210,"start":211,"enrollment":45,"conditions":212,"interventions":214},"NCT00806468","Effect of Desmopressin on the Nocturnal Micturition Frequency in Patients With Parkinson Disease","TERMINATED",[40],"2010-12","2011-02","2009-02",[213],"Parkinson Disease",[192],{"trials":216,"activeCount":11},[],{"intervention":218,"totalTrials":45,"cells":219},"Ranibizumab",{"EARLY_PHASE1":220,"PHASE1":222,"PHASE2":224,"PHASE3":226,"PHASE4":228,"NA":241},{"trials":221,"activeCount":11},[],{"trials":223,"activeCount":11},[],{"trials":225,"activeCount":11},[],{"trials":227,"activeCount":11},[],{"trials":229,"activeCount":11},[230],{"nctId":231,"briefTitle":232,"status":143,"phases":233,"primaryCompletion":234,"completion":235,"start":236,"enrollment":237,"conditions":238,"interventions":240},"NCT02843490","Functional and Structural Outcomes in Neovascular Age-related Macular Degeneration",[40],"2017-08-17","2017-11-09","2016-08-05",71,[239],"Neovascular Age-related Macular Degeneration",[218],{"trials":242,"activeCount":11},[],{"intervention":244,"totalTrials":45,"cells":245},"Levetiracetam",{"EARLY_PHASE1":246,"PHASE1":248,"PHASE2":250,"PHASE3":252,"PHASE4":254,"NA":269},{"trials":247,"activeCount":11},[],{"trials":249,"activeCount":11},[],{"trials":251,"activeCount":11},[],{"trials":253,"activeCount":11},[],{"trials":255,"activeCount":11},[256],{"nctId":257,"briefTitle":258,"status":143,"phases":259,"primaryCompletion":260,"completion":261,"start":262,"enrollment":263,"conditions":264,"interventions":266},"NCT00438451","Study on the Treatment of Elderly Patients With Older and Newer Antiepileptic Drugs",[40],"2010-07","2011-08","2007-01",361,[265],"Focal Epilepsy",[244,267,268],"Carbamazepine","Lamotrigine",{"trials":270,"activeCount":11},[],{"intervention":267,"totalTrials":45,"cells":272},{"EARLY_PHASE1":273,"PHASE1":275,"PHASE2":277,"PHASE3":279,"PHASE4":281,"NA":287},{"trials":274,"activeCount":11},[],{"trials":276,"activeCount":11},[],{"trials":278,"activeCount":11},[],{"trials":280,"activeCount":11},[],{"trials":282,"activeCount":11},[283],{"nctId":257,"briefTitle":258,"status":143,"phases":284,"primaryCompletion":260,"completion":261,"start":262,"enrollment":263,"conditions":285,"interventions":286},[40],[265],[244,267,268],{"trials":288,"activeCount":11},[],{"intervention":268,"totalTrials":45,"cells":290},{"EARLY_PHASE1":291,"PHASE1":293,"PHASE2":295,"PHASE3":297,"PHASE4":299,"NA":305},{"trials":292,"activeCount":11},[],{"trials":294,"activeCount":11},[],{"trials":296,"activeCount":11},[],{"trials":298,"activeCount":11},[],{"trials":300,"activeCount":11},[301],{"nctId":257,"briefTitle":258,"status":143,"phases":302,"primaryCompletion":260,"completion":261,"start":262,"enrollment":263,"conditions":303,"interventions":304},[40],[265],[244,267,268],{"trials":306,"activeCount":11},[],{"intervention":308,"totalTrials":45,"cells":309},"Vitamin D3",{"EARLY_PHASE1":310,"PHASE1":312,"PHASE2":314,"PHASE3":316,"PHASE4":318,"NA":331},{"trials":311,"activeCount":11},[],{"trials":313,"activeCount":11},[],{"trials":315,"activeCount":11},[],{"trials":317,"activeCount":11},[],{"trials":319,"activeCount":11},[320],{"nctId":321,"briefTitle":322,"status":207,"phases":323,"primaryCompletion":324,"completion":325,"start":326,"enrollment":327,"conditions":328,"interventions":330},"NCT02424552","Effect of Vitamin D as add-on Therapy for Vitamin D Insufficient Patients With Severe Asthma",[40],"2017-02-09","2017-03-09","2015-06-26",54,[329],"Asthma",[308],{"trials":332,"activeCount":11},[],{"intervention":334,"totalTrials":45,"cells":335},"Empagliflozin",{"EARLY_PHASE1":336,"PHASE1":338,"PHASE2":340,"PHASE3":342,"PHASE4":344,"NA":358},{"trials":337,"activeCount":11},[],{"trials":339,"activeCount":11},[],{"trials":341,"activeCount":11},[],{"trials":343,"activeCount":11},[],{"trials":345,"activeCount":11},[346],{"nctId":347,"briefTitle":348,"status":143,"phases":349,"primaryCompletion":350,"completion":351,"start":352,"enrollment":353,"conditions":354,"interventions":357},"NCT02932436","Effects of Empagliflozin on Left Ventricular Diastolic Function Compared to Usual Care in Type 2 Diabetics",[40],"2020-06-15","2020-08-31","2016-10-10",144,[355,356],"Diabetes Mellitus, Type 2","Diastolic Dysfunction",[334],{"trials":359,"activeCount":11},[],{"intervention":361,"totalTrials":45,"cells":362},"Formoterol",{"EARLY_PHASE1":363,"PHASE1":365,"PHASE2":367,"PHASE3":369,"PHASE4":371,"NA":383},{"trials":364,"activeCount":11},[],{"trials":366,"activeCount":11},[],{"trials":368,"activeCount":11},[],{"trials":370,"activeCount":11},[],{"trials":372,"activeCount":11},[373],{"nctId":374,"briefTitle":375,"status":143,"phases":376,"completion":377,"start":378,"enrollment":379,"conditions":380,"interventions":382},"NCT00561886","Change of Inspiratory Peak Flow in COPD",[40],"2007-10","2007-04",40,[381],"Chronic Obstructive Pulmonary Disease",[361],{"trials":384,"activeCount":11},[],{"intervention":386,"totalTrials":45,"cells":387},"Mepolizumab",{"EARLY_PHASE1":388,"PHASE1":390,"PHASE2":392,"PHASE3":394,"PHASE4":405,"NA":407},{"trials":389,"activeCount":11},[],{"trials":391,"activeCount":11},[],{"trials":393,"activeCount":11},[],{"trials":395,"activeCount":11},[396],{"nctId":397,"briefTitle":398,"status":207,"phases":399,"primaryCompletion":400,"completion":400,"start":401,"enrollment":402,"conditions":403,"interventions":404},"NCT02594332","Effects of Mepolizumab Compared to Placebo on Airway Physiology in Patients With Eosinophilic Asthma: MEMORY Study",[39],"2017-05-22","2015-11-17",29,[329],[386],{"trials":406,"activeCount":11},[],{"trials":408,"activeCount":11},[],{"intervention":410,"totalTrials":31,"cells":411},"Cabozantinib",{"EARLY_PHASE1":412,"PHASE1":414,"PHASE2":416,"PHASE3":437,"PHASE4":439,"NA":441},{"trials":413,"activeCount":11},[],{"trials":415,"activeCount":11},[],{"trials":417,"activeCount":11},[418,428],{"nctId":419,"briefTitle":420,"status":60,"phases":421,"primaryCompletion":422,"completion":423,"start":424,"enrollment":425,"conditions":426,"interventions":427},"NCT04454762","A Study to Evaluate the Safety, Tolerability and Efficacy of Cabozantinib in Patients With Hepatocellular Carcinoma and Impaired Liver Function",[38],"2023-08-01","2024-02-01","2020-07-22",20,[24],[410],{"nctId":429,"briefTitle":430,"status":207,"phases":431,"primaryCompletion":432,"completion":432,"start":433,"enrollment":16,"conditions":434,"interventions":436},"NCT04066595","Cabozantinib in Patients With Locally Advanced or Metastatic Urothelial Cell Carcinoma.",[38],"2021-07-01","2020-02-10",[435],"Urothelial Carcinoma",[410],{"trials":438,"activeCount":11},[],{"trials":440,"activeCount":11},[],{"trials":442,"activeCount":11},[],{"intervention":444,"totalTrials":31,"cells":445},"Sorafenib",{"EARLY_PHASE1":446,"PHASE1":448,"PHASE2":450,"PHASE3":474,"PHASE4":476,"NA":478},{"trials":447,"activeCount":11},[],{"trials":449,"activeCount":11},[],{"trials":451,"activeCount":11},[452,462],{"nctId":453,"briefTitle":454,"status":207,"phases":455,"primaryCompletion":456,"completion":456,"start":457,"enrollment":458,"conditions":459,"interventions":461},"NCT00532025","Sorafenib in Resected Non-small Cell Lung Carcinoma",[38],"2008-09","2007-09",134,[460],"Carcinoma, Non-Small-Cell Lung",[444],{"nctId":463,"briefTitle":464,"status":60,"phases":465,"primaryCompletion":466,"completion":467,"start":468,"enrollment":469,"conditions":470,"interventions":471},"NCT03645980","DKN-01 Inhibition in Advanced Liver Cancer",[37,38],"2021-08-31","2022-08-31","2018-10-10",70,[24],[472,473,444],"DKN-01 300 mg","DKN-01 600 mg",{"trials":475,"activeCount":11},[],{"trials":477,"activeCount":11},[],{"trials":479,"activeCount":11},[],{"intervention":481,"totalTrials":45,"cells":482},"Cisplatin, Irinotecan, Capecitabine",{"EARLY_PHASE1":483,"PHASE1":485,"PHASE2":487,"PHASE3":498,"PHASE4":500,"NA":502},{"trials":484,"activeCount":11},[],{"trials":486,"activeCount":11},[],{"trials":488,"activeCount":11},[489],{"nctId":490,"briefTitle":491,"status":143,"phases":492,"completion":377,"start":493,"enrollment":494,"conditions":495,"interventions":497},"NCT00675194","Efficacy of Irinotecan and Capecitabine Versus(vs) Cisplatin and Capecitabine in Patients With Esophago-Gastric Cancer",[38],"2003-10",120,[496],"Gastric Cancer",[481],{"trials":499,"activeCount":11},[],{"trials":501,"activeCount":11},[],{"trials":503,"activeCount":11},[],{"intervention":505,"totalTrials":45,"cells":506},"Dabigatran etexilate",{"EARLY_PHASE1":507,"PHASE1":509,"PHASE2":511,"PHASE3":525,"PHASE4":527,"NA":529},{"trials":508,"activeCount":11},[],{"trials":510,"activeCount":11},[],{"trials":512,"activeCount":11},[513],{"nctId":514,"briefTitle":515,"status":207,"phases":516,"primaryCompletion":517,"completion":517,"start":518,"enrollment":519,"conditions":520,"interventions":523},"NCT02256683","Resolution of Left Atrial-Appendage Thrombus - Effects of Dabigatran in Patients With AF",[38],"2018-05","2014-07",64,[521,522],"Atrial Fibrillation or Atrial Flutter","Thrombosis of Left Atrial Appendage",[505,524],"Phenprocoumon",{"trials":526,"activeCount":11},[],{"trials":528,"activeCount":11},[],{"trials":530,"activeCount":11},[],{"intervention":524,"totalTrials":45,"cells":532},{"EARLY_PHASE1":533,"PHASE1":535,"PHASE2":537,"PHASE3":543,"PHASE4":545,"NA":547},{"trials":534,"activeCount":11},[],{"trials":536,"activeCount":11},[],{"trials":538,"activeCount":11},[539],{"nctId":514,"briefTitle":515,"status":207,"phases":540,"primaryCompletion":517,"completion":517,"start":518,"enrollment":519,"conditions":541,"interventions":542},[38],[521,522],[505,524],{"trials":544,"activeCount":11},[],{"trials":546,"activeCount":11},[],{"trials":548,"activeCount":11},[],{"intervention":550,"totalTrials":45,"cells":551},"Docetaxel, Oxaliplatin",{"EARLY_PHASE1":552,"PHASE1":554,"PHASE2":556,"PHASE3":569,"PHASE4":571,"NA":573},{"trials":553,"activeCount":11},[],{"trials":555,"activeCount":11},[],{"trials":557,"activeCount":11},[558],{"nctId":559,"briefTitle":560,"status":143,"phases":561,"primaryCompletion":562,"completion":562,"start":563,"enrollment":564,"conditions":565,"interventions":568},"NCT00374985","Safety and Efficacy of Neoadjuvant Radiochemotherapy in Adenocarcinoma of the Gastric-oesophageal Junction",[37,38],"2013-09","2005-10",25,[566,567],"Esophageal Neoplasms","Stomach Neoplasms",[550],{"trials":570,"activeCount":11},[],{"trials":572,"activeCount":11},[],{"trials":574,"activeCount":11},[],{"intervention":576,"totalTrials":45,"cells":577},"Sunitinib-Malate",{"EARLY_PHASE1":578,"PHASE1":580,"PHASE2":582,"PHASE3":596,"PHASE4":598,"NA":600},{"trials":579,"activeCount":11},[],{"trials":581,"activeCount":11},[],{"trials":583,"activeCount":11},[584],{"nctId":585,"briefTitle":586,"status":143,"phases":587,"primaryCompletion":588,"completion":589,"start":590,"enrollment":591,"conditions":592,"interventions":595},"NCT00411151","Efficacy and Safety of Sunitinib in Metastatic Gastric Cancer",[38],"2009-07","2009-08","2006-12",52,[593,594],"Gastric Adenocarcinoma","Barrett Esophagus",[576],{"trials":597,"activeCount":11},[],{"trials":599,"activeCount":11},[],{"trials":601,"activeCount":11},[],{"intervention":603,"totalTrials":45,"cells":604},"Vinorelbine",{"EARLY_PHASE1":605,"PHASE1":607,"PHASE2":609,"PHASE3":621,"PHASE4":623,"NA":625},{"trials":606,"activeCount":11},[],{"trials":608,"activeCount":11},[],{"trials":610,"activeCount":11},[611],{"nctId":612,"briefTitle":613,"status":143,"phases":614,"primaryCompletion":615,"completion":615,"start":616,"enrollment":617,"conditions":618,"interventions":620},"NCT03007992","Metronomic Treatment With Daily Oral Vinorelbine as First-line Chemotherapy in Patients With Advanced\u002FMetastatic Hormone Receptor Positive (HR+)\u002FHuman Epidermal Growth Factor Receptor 2 Negative (HER2-) Breast Cancer",[38],"2019-03-02","2016-12",9,[619],"Metastatic Breast Cancer",[603],{"trials":622,"activeCount":11},[],{"trials":624,"activeCount":11},[],{"trials":626,"activeCount":11},[],{"intervention":628,"totalTrials":45,"cells":629},"Pegylated interferon alfa-2a plus nucleos",{"EARLY_PHASE1":630,"PHASE1":632,"PHASE2":634,"PHASE3":645,"PHASE4":647,"NA":649},{"trials":631,"activeCount":11},[],{"trials":633,"activeCount":11},[],{"trials":635,"activeCount":11},[636],{"nctId":637,"briefTitle":638,"status":143,"phases":639,"primaryCompletion":640,"completion":640,"start":147,"enrollment":641,"conditions":642,"interventions":644},"NCT01524679","Peg-interferon ADDed to an Ongoing Nucleos(t)Ide Based Treatment in Patients With Chronic Hepatitis B to Induce Decrease of HBs-Antigen",[38],"2017-08-28",170,[643],"Chronic Hepatitis B",[628],{"trials":646,"activeCount":11},[],{"trials":648,"activeCount":11},[],{"trials":650,"activeCount":11},[],{"intervention":652,"totalTrials":45,"cells":653},"combination of Avelumab and Cabozantinib",{"EARLY_PHASE1":654,"PHASE1":656,"PHASE2":658,"PHASE3":670,"PHASE4":672,"NA":674},{"trials":655,"activeCount":11},[],{"trials":657,"activeCount":11},[],{"trials":659,"activeCount":11},[660],{"nctId":661,"briefTitle":662,"status":60,"phases":663,"primaryCompletion":664,"completion":665,"start":666,"enrollment":667,"conditions":668,"interventions":669},"NCT05289856","Cabozantinib in Combination With Avelumab in Patients Refractory to Standard Chemotherapy With Advanced Neuroendocrine Neoplasias G3 (NEN G3)",[38],"2025-03-01","2025-12-01","2022-03-28",30,[28],[652],{"trials":671,"activeCount":11},[],{"trials":673,"activeCount":11},[],{"trials":675,"activeCount":11},[],{"intervention":472,"totalTrials":45,"cells":677},{"EARLY_PHASE1":678,"PHASE1":680,"PHASE2":682,"PHASE3":688,"PHASE4":690,"NA":692},{"trials":679,"activeCount":11},[],{"trials":681,"activeCount":11},[],{"trials":683,"activeCount":11},[684],{"nctId":463,"briefTitle":464,"status":60,"phases":685,"primaryCompletion":466,"completion":467,"start":468,"enrollment":469,"conditions":686,"interventions":687},[37,38],[24],[472,473,444],{"trials":689,"activeCount":11},[],{"trials":691,"activeCount":11},[],{"trials":693,"activeCount":11},[],{"intervention":473,"totalTrials":45,"cells":695},{"EARLY_PHASE1":696,"PHASE1":698,"PHASE2":700,"PHASE3":706,"PHASE4":708,"NA":710},{"trials":697,"activeCount":11},[],{"trials":699,"activeCount":11},[],{"trials":701,"activeCount":11},[702],{"nctId":463,"briefTitle":464,"status":60,"phases":703,"primaryCompletion":466,"completion":467,"start":468,"enrollment":469,"conditions":704,"interventions":705},[37,38],[24],[472,473,444],{"trials":707,"activeCount":11},[],{"trials":709,"activeCount":11},[],{"trials":711,"activeCount":11},[],{"intervention":713,"totalTrials":45,"cells":714},"Varenicline",{"EARLY_PHASE1":715,"PHASE1":717,"PHASE2":719,"PHASE3":730,"PHASE4":732,"NA":734},{"trials":716,"activeCount":11},[],{"trials":718,"activeCount":11},[],{"trials":720,"activeCount":11},[721],{"nctId":722,"briefTitle":723,"status":60,"phases":724,"primaryCompletion":725,"completion":725,"start":726,"enrollment":379,"conditions":727,"interventions":729},"NCT01071187","Varenicline for Alcohol Dependence",[38],"2011-09","2010-03",[728],"Alcohol Dependence",[713],{"trials":731,"activeCount":11},[],{"trials":733,"activeCount":11},[],{"trials":735,"activeCount":11},[],{"intervention":737,"totalTrials":45,"cells":738},"Obinutuzumab and Pixantrone",{"EARLY_PHASE1":739,"PHASE1":741,"PHASE2":743,"PHASE3":755,"PHASE4":757,"NA":759},{"trials":740,"activeCount":11},[],{"trials":742,"activeCount":11},[],{"trials":744,"activeCount":11},[745],{"nctId":746,"briefTitle":747,"status":143,"phases":748,"primaryCompletion":749,"completion":750,"start":751,"enrollment":469,"conditions":752,"interventions":754},"NCT02499003","GOAL: GA101 Plus Pixantrone for Relapsed Aggressive Lymphoma",[38],"2019-01-02","2022-01-02","2015-08-14",[753],"Lymphoma, Non-Hodgkin",[737],{"trials":756,"activeCount":11},[],{"trials":758,"activeCount":11},[],{"trials":760,"activeCount":11},[],{"intervention":762,"totalTrials":45,"cells":763},"Cetuximab IF",{"EARLY_PHASE1":764,"PHASE1":766,"PHASE2":768,"PHASE3":780,"PHASE4":782,"NA":784},{"trials":765,"activeCount":11},[],{"trials":767,"activeCount":11},[],{"trials":769,"activeCount":11},[770],{"nctId":771,"briefTitle":772,"status":143,"phases":773,"primaryCompletion":774,"completion":774,"start":775,"enrollment":776,"conditions":777,"interventions":779},"NCT01123811","Efficacy of Cetuximab in Combination With Irinotecan and 5- FU\u002FFA in Treatment of Metastatic Gastric Cancer",[38],"2010-05","2006-05",45,[778],"Adenocarcinoma of Stomach or Esophagogastric Junction",[762],{"trials":781,"activeCount":11},[],{"trials":783,"activeCount":11},[],{"trials":785,"activeCount":11},[],{"intervention":787,"totalTrials":45,"cells":788},"Avelumab",{"EARLY_PHASE1":789,"PHASE1":791,"PHASE2":793,"PHASE3":804,"PHASE4":806,"NA":808},{"trials":790,"activeCount":11},[],{"trials":792,"activeCount":11},[],{"trials":794,"activeCount":11},[795],{"nctId":796,"briefTitle":797,"status":143,"phases":798,"primaryCompletion":799,"completion":799,"start":800,"enrollment":801,"conditions":802,"interventions":803},"NCT03352934","Avelumab Treatment in Patients With Neuroendocrine Carcinomas (NEC G3) Progressive After Chemotherapy",[38],"2022-02-18","2017-12-07",60,[28],[787],{"trials":805,"activeCount":11},[],{"trials":807,"activeCount":11},[],{"trials":809,"activeCount":11},[],{"intervention":811,"totalTrials":45,"cells":812},"BIBW 2992",{"EARLY_PHASE1":813,"PHASE1":815,"PHASE2":825,"PHASE3":827,"PHASE4":829,"NA":831},{"trials":814,"activeCount":11},[],{"trials":816,"activeCount":11},[817],{"nctId":818,"briefTitle":819,"status":207,"phases":820,"primaryCompletion":821,"completion":821,"start":147,"enrollment":617,"conditions":822,"interventions":824},"NCT01679405","BIBW 2992 as add-on to Gem\u002FCis in Advanced Biliary Tract Cancer",[37],"2016-04",[823],"Metastatic Disease",[811],{"trials":826,"activeCount":11},[],{"trials":828,"activeCount":11},[],{"trials":830,"activeCount":11},[],{"trials":832,"activeCount":11},[],{"intervention":834,"totalTrials":31,"cells":835},"Plenvu",{"EARLY_PHASE1":836,"PHASE1":838,"PHASE2":840,"PHASE3":842,"PHASE4":844,"NA":846},{"trials":837,"activeCount":11},[],{"trials":839,"activeCount":11},[],{"trials":841,"activeCount":11},[],{"trials":843,"activeCount":11},[],{"trials":845,"activeCount":11},[],{"trials":847,"activeCount":11},[848,861],{"nctId":849,"briefTitle":850,"status":60,"phases":851,"primaryCompletion":852,"completion":853,"start":854,"enrollment":855,"conditions":856,"interventions":860},"NCT04456231","QR Code for Endoscopic Bowel Preparation",[],"2021-01","2021-06","2020-09",404,[857,858,859],"Quality Standards in Colonoscopy","Patient Education","Acceptance of Bowel-preparation",[834],{"nctId":862,"briefTitle":863,"status":60,"phases":864,"primaryCompletion":852,"completion":865,"start":854,"enrollment":866,"conditions":867,"interventions":870},"NCT04457934","Effectiveness of PLENVU in the General Screening Population and Patients With IBD",[],"2021-08",290,[868,869],"IBD","Healthy",[834],{"intervention":872,"totalTrials":45,"cells":873},"Disulfiram",{"EARLY_PHASE1":874,"PHASE1":876,"PHASE2":878,"PHASE3":880,"PHASE4":882,"NA":884},{"trials":875,"activeCount":11},[],{"trials":877,"activeCount":11},[],{"trials":879,"activeCount":11},[],{"trials":881,"activeCount":11},[],{"trials":883,"activeCount":11},[],{"trials":885,"activeCount":11},[886],{"nctId":887,"briefTitle":888,"status":143,"phases":889,"primaryCompletion":890,"completion":891,"start":892,"enrollment":893,"conditions":894,"interventions":896},"NCT03212599","Disulfiram as a Modulator of Amyloid Precursor Protein-processing",[],"2016-06","2017-07","2013-05",17,[895],"Alcohol Addiction",[872]]